Cell line · CVCL_0001
Papers56
1 to 20 of 56
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Greatwall kinase regulates acute myeloid leukaemia cell division through a non-canonical mechanism. | EMBO Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| A trifluoromethyl quinazoline inhibits hepatocellular carcinoma proliferation through HDAC1 binding and multi-target mechanisms. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Variant-specific interaction of kinectin 1 with the multi-tRNA synthetase complex regulates ER sheet organization. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Cancer cell death induced by the NAD antimetabolite Vacor discloses the antitumor potential of SARM1. | FEBS Lett | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting scavenger receptor class B type 1 with a bioinspired ligand induces apoptosis or ferroptosis in AML. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Platelets sequester extracellular DNA, capturing tumor-derived and free fetal DNA. | Science | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic Evaluation of GAPs and GEFs Identifies a Targetable Dependency for Hematopoietic Malignancies. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL Leukemia. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Aberrant expression of human endogenous retrovirus K9-derived elements is associated with better clinical outcome of acute myelocytic leukemia. | Retrovirology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2-Mutated Clonal Hematopoiesis. | Cancer Discov | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Non-canonical Hedgehog signaling mediates profibrotic hematopoiesis-stroma crosstalk in myeloproliferative neoplasms. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML. | Cell Rep Med | 2023 | Its Methods give the RRID and name the line | PubMed | |
| TSC22D3 as an immune-related prognostic biomarker for acute myeloid leukemia. | iScience | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BET Proteins Downregulates miR-33a To Promote Synergy with PIM Inhibitors in CMML. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Choosing the Right Cell Line for Acute Myeloid Leukemia (AML) Research. | Int J Mol Sci | 2023 | Cellosaurus cites it | PubMed | |
| Transcriptionally imprinted glycomic signatures of acute myeloid leukemia. | Cell Biosci | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Crizotinib Has Preclinical Efficacy in Philadelphia-Negative Myeloproliferative Neoplasms. | Clin Cancer Res | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_0001/papers